Shorter proton therapy after mastectomy shows promise in reducing side effects
NCT ID NCT02783690
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compared two different schedules of proton therapy after mastectomy in 88 women with breast cancer. One group received 15 treatments, the other 25, to see if the shorter course was as safe and effective. The goal was to reduce side effects and treatment burden without compromising cancer control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
88 people
The number who actually took part.
- Started
-
May 2016
- Finished
-
Nov 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria * Age ≥ 18 years * Histologic confirmation of breast cancer resected by mastectomy with or without immediate reconstruction and chest wall and regional nodal irradiation planned. * pStage T1-T4N0-N3M0 or ypStage T0-4N0-N3M0 Note: The axilla must be staged by sentinel node biopsy alone, sentinel node biopsy followed by axillary node dissection, or axillary lymph node dissection alone * ECOG Performance Status (PS) 0 to 2. (Appendix I). * Negative pregnancy test done ≤7 days prior to registration, for women of childbearing potential only. * Radiotherapy must begin within 12 weeks of last surgery (breast or axilla) or last chemotherapy. Note: Breast implants and expanders allowed * Able to and provides IRB approved study specific written informed consent * Ability to complete questionnaire (s) by themselves or with assistance * Able to complete all mandatory tests listed in section 4.0 * Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study) * Willing to provide tissue and blood samples for correlative research purposes. * Rochester and Arizona patients: Willing to sign consent onto the Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking study, IRB number 15-000136 * Rochester patients: Willing to sign consent onto Evaluation of cardiac function in patients undergoing proton beam or photon radiotherapy, IRB number 15-007443 Exclusion Criteria: * Medical contraindication to receipt of radiotherapy. * Severe active co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or providing informed consent. * Active systemic lupus or scleroderma. * Pregnancy or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception * Prior receipt of ipsilateral breast or chest wall radiation that would result in significant overlap of radiation therapy fields. Prior contralateral radiotherapy for breast cancer is allowed. * Positive margins after definitive surgery * History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior study entry * Inflammatory breast cancer * Recurrent Breast Cancer * Boosts to the chest wall after mastectomy. Nodal boosts are allowed.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a faster radiation course match the standard one after breast reconstruction?
- Can High-Risk breast cancer patients skip an extra radiation boost?
- Radioactive probe lights up CD73 on breast tumors in PET scans
- Can time with horses help cancer patients feel better?
- Can an oral drug replace injections for advanced breast cancer?
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?